Revatio FDA Approval History
FDA Approved: Yes (First approved June 3, 2005)
Brand name: Revatio
Generic name: sildenafil citrate
Company: Pfizer Inc.
Treatment for: Pulmonary Arterial Hypertension
Revatio (sildenafil) is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension.
Development timeline for Revatio
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.